semaglutide cardiovascular outcomes news today 2025 VisualAbstract: and in Obesity without Diabetes semaglutide cardiovascular outcomes 2025 news

Our natural NAD levels start to decline with age, leading to slower skin repair, visible aging, and a weaker skin barrier

GLP-1 receptor agonists offer a safe, medically supported path to weight loss for individuals who have struggled with traditional methods

In a 72-week trial for type 2 diabetes, patients using Mounjaro on the highest titrated dose of 15 mg for the last 40 weeks lost about 16 percent of their initial weight

from the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus

Ozempic is a brand-name medication that contains semaglutide and is FDA-approved for type 2 diabetes